Psychiatric Comorbidities in Pediatric Monogenic Diabetes due to GCK Mutation : Impact on Diabetes-Related Quality of Life
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Monogenic diabetes caused by mutation in the glucokinase gene (GCK-MD) is a rare disorder manifesting in childhood as mild, prevalent hyperglycemia. By consensus, it is managed by dietary supervision and infrequent consultations. However, its impact on the mental health of the affected children is largely unknown.
OBJECTIVE: To estimate the prevalence of psychiatric comorbidities in children with monogenic glucokinase-related diabetes (GCK-MD) and evaluate their association with quality of life (QoL).
METHODS: The study invited children with GCK-MD aged 5-18 years identified in the Central National Registry and treated in 3 pediatric diabetes centers in Poland. The control group comprised children with type 1 diabetes (T1D, the most common diabetes type in youth) matched for age and family history of diabetes. Participants underwent a semistructured clinical interview diagnostic for psychiatric comorbidities, questionnaires assessing behavioral problems, depressive symptoms, parental stress, and measuring general and diabetes-related QoL (PedsQl).
RESULTS: We included 35 patients with GCK-MDMD and 199 with T1D. Eight (22.9%) GCK-MD patients were diagnosed with psychiatric disorder in their lifetime, compared with 16 (8.1%) in the T1D group (odds ratio 3.4 [95% confidence interval: 1.3-8.7]). Patients with GCK-MD showed better parent-reported general QoL (87.1 ± 11.9 vs 82.0 ± 14.0, P = 0.0060) and higher diabetes-related QoL in both parental (84.5 ± 13.8 vs 74.1 ± 15.2, P < 0.0001) and child's perspective (87.6 ± 10.9 vs 77.3 ± 13.9, P < 0.0001). Psychiatric disorders (+P) were associated with worse child-reported diabetes QoL (T1D+P 66.6 ± 16.7, T1D-P 78.2 ± 13.3, GCK-MD+P 79.6 ± 16.3, GCK-MD-P 90.1 ± 7.5, P = 0.0002).
CONCLUSIONS: High prevalence of psychiatric disorders in children with GCK-MD and lower QoL emphasizes the need for psychologic surveillance in those otherwise mildly-treated patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Journal of the Academy of Consultation-Liaison Psychiatry - 63(2022), 6 vom: 06. Nov., Seite 548-556 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Michalak, Arkadiusz [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 2.7.1.2 |
|---|
| Anmerkungen: |
Date Completed 27.12.2022 Date Revised 27.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaclp.2022.03.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339111879 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339111879 | ||
| 003 | DE-627 | ||
| 005 | 20231226002157.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaclp.2022.03.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1130.xml |
| 035 | |a (DE-627)NLM339111879 | ||
| 035 | |a (NLM)35381380 | ||
| 035 | |a (PII)S2667-2960(22)00028-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Michalak, Arkadiusz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Psychiatric Comorbidities in Pediatric Monogenic Diabetes due to GCK Mutation |b Impact on Diabetes-Related Quality of Life |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.12.2022 | ||
| 500 | |a Date Revised 27.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Monogenic diabetes caused by mutation in the glucokinase gene (GCK-MD) is a rare disorder manifesting in childhood as mild, prevalent hyperglycemia. By consensus, it is managed by dietary supervision and infrequent consultations. However, its impact on the mental health of the affected children is largely unknown | ||
| 520 | |a OBJECTIVE: To estimate the prevalence of psychiatric comorbidities in children with monogenic glucokinase-related diabetes (GCK-MD) and evaluate their association with quality of life (QoL) | ||
| 520 | |a METHODS: The study invited children with GCK-MD aged 5-18 years identified in the Central National Registry and treated in 3 pediatric diabetes centers in Poland. The control group comprised children with type 1 diabetes (T1D, the most common diabetes type in youth) matched for age and family history of diabetes. Participants underwent a semistructured clinical interview diagnostic for psychiatric comorbidities, questionnaires assessing behavioral problems, depressive symptoms, parental stress, and measuring general and diabetes-related QoL (PedsQl) | ||
| 520 | |a RESULTS: We included 35 patients with GCK-MDMD and 199 with T1D. Eight (22.9%) GCK-MD patients were diagnosed with psychiatric disorder in their lifetime, compared with 16 (8.1%) in the T1D group (odds ratio 3.4 [95% confidence interval: 1.3-8.7]). Patients with GCK-MD showed better parent-reported general QoL (87.1 ± 11.9 vs 82.0 ± 14.0, P = 0.0060) and higher diabetes-related QoL in both parental (84.5 ± 13.8 vs 74.1 ± 15.2, P < 0.0001) and child's perspective (87.6 ± 10.9 vs 77.3 ± 13.9, P < 0.0001). Psychiatric disorders (+P) were associated with worse child-reported diabetes QoL (T1D+P 66.6 ± 16.7, T1D-P 78.2 ± 13.3, GCK-MD+P 79.6 ± 16.3, GCK-MD-P 90.1 ± 7.5, P = 0.0002) | ||
| 520 | |a CONCLUSIONS: High prevalence of psychiatric disorders in children with GCK-MD and lower QoL emphasizes the need for psychologic surveillance in those otherwise mildly-treated patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a GCK-MD | |
| 650 | 4 | |a glucokinase | |
| 650 | 4 | |a monogenic diabetes | |
| 650 | 4 | |a psychiatric disorder | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a type 1 diabetes | |
| 650 | 7 | |a Glucokinase |2 NLM | |
| 650 | 7 | |a EC 2.7.1.2 |2 NLM | |
| 700 | 1 | |a Szadkowska, Agnieszka |e verfasserin |4 aut | |
| 700 | 1 | |a Mlynarski, Wojciech |e verfasserin |4 aut | |
| 700 | 1 | |a Myśliwiec, Małgorzata |e verfasserin |4 aut | |
| 700 | 1 | |a Deja, Grażyna |e verfasserin |4 aut | |
| 700 | 1 | |a Skała-Zamorowska, Eliza |e verfasserin |4 aut | |
| 700 | 1 | |a Jarosz-Chobot, Przemysława |e verfasserin |4 aut | |
| 700 | 1 | |a Borowiec, Maciej |e verfasserin |4 aut | |
| 700 | 1 | |a Zalepa, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Musiał-Paździor, Malwina |e verfasserin |4 aut | |
| 700 | 1 | |a Gierak, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Kaźmierczak-Mytkowska, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Wolańczyk, Tomasz |e verfasserin |4 aut | |
| 700 | 1 | |a Fendler, Wojciech |e verfasserin |4 aut | |
| 700 | 1 | |a Butwicka, Agnieszka |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the Academy of Consultation-Liaison Psychiatry |d 2021 |g 63(2022), 6 vom: 06. Nov., Seite 548-556 |w (DE-627)NLM308649796 |x 2667-2960 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2022 |g number:6 |g day:06 |g month:11 |g pages:548-556 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaclp.2022.03.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2022 |e 6 |b 06 |c 11 |h 548-556 | ||